While the identification of molecular alterations, such as isocitrate dehydrogenase IDH1/2 mutations, 1p/19q codeletion, and MGMT promoter methylation, has improved the accuracy of diagnostics, prognostication, and prediction of treatment response for glioma patients, there has been no tangible improvement in clinical management and patient outcomes. This evidence concerns the gene MGMT and glioma.